Searchable abstracts of presentations at key conferences in endocrinology

ea0049s12.3 | New development in Graves' Orbitopathy | ECE2017

How to predict progression in Graves orbitopathy?

Perros Petros

Graves’ orbitopathy (GO) is a relatively rare condition, but can cause significant morbidity, poor quality of life, socioeconomic cost and occasionally impaired vision. Some studies indicate that nearly all patients with Graves’ hyperthyroidism, even those without overt GO, have subclinical eye disease. It is becoming increasingly evident that early recognition of GO and early interventions can affect the long-term outcome favourably. Predicting which patients will d...

ea0044s10.1 | Clinical thyroidology update | SFEBES2016

Thyroid incidentalomas, US, CT, MR and PET

Perros Petros

Over the past two decades, the developed world has witnessed an epidemic of incidental thyroid nodules diagnosed through imaging of the neck for other indications. This has created new challenges for patients and clinicians. Several guidelines have been published in the past 2 years on this topic, which are broadly concordant and only differ in detail. Optimal management is based on the following principles: 1. Avoidance of imaging unless there is a clea...

ea0059cmw5.3 | Workshop 5: How do I. . . (2) | SFEBES2018

How do I manage thyroid eye disease?

Perros Petros

Evidence is emerging from the UK and elsewhere that: (a) endocrine clinics are reservoirs of undiagnosed thyroid eye disease (TED); (b) the interval from onset of symptoms of TED to diagnosis and treatment often exceeds 1 year; (c) simple interventions that can be initiated in the endocrine clinic can reverse mild TED and prevent progression; (d) immunosuppressive treatments work best in the first 9 months. Early detection of TED is a fundamental part of management and can be ...

ea0038mte8 | (1) | SFEBES2015

Meet the Expert 8: updated thyroid cancer guidelines

Perros Petros

Previous UK guidelines (2002, 2007) focused on reducing regional variations in practice, concentrating expertise (especially surgical), and eliminating clinical, radiological and biochemical evidence of persistent disease. The 2014 guidelines aim to improve the overall survival while enhancing the health-related quality of life of patients. This presentation will discuss areas of the guidelines that are significantly different from the previous edition of the guidelines and ar...

ea0021cm4.1 | The management of thyroid cancer | SFEBES2009

Investigation of thyroid cancer from thyroid lump to surgical referral

Perros Petros

The introduction of fine needle aspiration biopsy revolutionised the investigation of thyroid nodules. Several decades on, diagnosis relies largely on the same technique. Meanwhile clinicians are faced with an epidemic of incidentally discovered thyroid nodules and an increasingly ‘informed’ public frequently misled by unreliable sources. Molecular diagnostics and new imaging techniques are in the horizon, but unlikely to influence clinical practice in the next few y...

ea0013s57 | Differentiated thyroid cancer | SFEBES2007

Clinical management of thyroid cancer: new guidelines

Perros Petros

Thyroid cancer is generally associated with a good prognosis, yet mortality in the UK was reported to be higher than other developed countries, and published audits have highlighted deficiencies in management of this condition in Scotland and England. The British Thyroid Association (BTA) responded by publishing national guidelines for the management of differentiated thyroid cancer in 2002. Since then, other guidelines and consensus statements have been published from Europe ...

ea0050p395 | Thyroid | SFEBES2017

Recent liothyronine price increases have changed primary care prescription practice, with increased referrals to specialist care

Terry Isabelle , Perros Petros , Moran Carla

Background: The cost of liothyronine (T3) has significantly increased, possibly affecting prescription practices.Methods: An online questionnaire was designed to assess current T3 use by UK endocrinologists and to determine whether the price increase resulted in a change in primary care prescription practices. Consultant grade members of the Society for Endocrinology Thyroid Network were invited to partake.Results: Re...

ea0050p395 | Thyroid | SFEBES2017

Recent liothyronine price increases have changed primary care prescription practice, with increased referrals to specialist care

Terry Isabelle , Perros Petros , Moran Carla

Background: The cost of liothyronine (T3) has significantly increased, possibly affecting prescription practices.Methods: An online questionnaire was designed to assess current T3 use by UK endocrinologists and to determine whether the price increase resulted in a change in primary care prescription practices. Consultant grade members of the Society for Endocrinology Thyroid Network were invited to partake.Results: Re...

ea0038p432 | Thyroid | SFEBES2015

Peripheral blood microRNA markers in patients with papillary thyroid cancer

Perros Petros , Mallick Ujjal , Pearce Simon

Monitoring patients with thyroid cancer for recurrent disease relies heavily on measuring serum thyroglobulin (Tg). Tg cannot be assessed reliably in the presence of anti-thyroglobulin antibodies for analytical reasons, this being the case in about a third of patients. There has been recent interest in microRNA profiling of fine needle aspiration biopsies of thyroid nodules, with encouraging results. The objective of this pilot was to explore microRNAs in peripheral blood of p...

ea0031p172 | Neoplasia, cancer and late effects | SFEBES2013

Gut carcinoid in a patient with horseshoe kidney and family history of carcinoid syndrome: a case report

Lois Konstantinos , James Andy , Perros Petros

Introduction: The familial risks of carcinoids are not clear. There has never been a report of gastrointestinal carcinoid coexisting with horseshoe kidney.Case presentation: We present the case of a 15 mm well differentiated metastatic small bowel NET with vascular and perineural invasion and three of four positive lymph nodes (Ki67: 1.9%, ENETS stage: pT4 pN1 pMX R1) in a 75-year-old British male with episodes of diarrhea and 24 h urinary 5HIAA: 48 (&#6...